Skip to main content
SpringerLink
Log in

Pemphigus Vulgaris: An Evidence-Based Treatment Update

  • Living reference work entry
  • First Online:
Cutaneous Biometrics

  • 138 Accesses

Abstract

Pemphigus vulgaris is a rare autoimmune blistering disease which is associated with high mortality and morbidity. The nature of this disease necessitates long-term aggressive treatment, for which systemic corticosteroid is the gold standard. However, the serious complications associated with systemic corticosteroids have led to the development of various adjuvant therapies including azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, cyclosporine, dapsone, gold compounds, plasmapheresis, tetracyclines, and topical therapies. The evidence to support these adjuvant therapies is extremely limited and comprises of small RCTs, case series, and case studies. Newer and emerging treatments including antitumor necrosis factor agents, intravenous immunoglobulin, and rituximab appear to be promising interventions. More research should be conducted to evaluate the efficacy of these treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(5):679–90.

    Article  CAS  PubMed  Google Scholar 

  • Ahmed AR, Gurcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011;25(9):1073–9.

    Article  CAS  PubMed  Google Scholar 

  • Akhtar SJ, Hasan MU. Treatment of pemphigus: a local experience. J Pak Med Assoc. 1998;48(10):300–4.

    CAS  PubMed  Google Scholar 

  • Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2–8.

    Article  CAS  PubMed  Google Scholar 

  • Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An ‘n-of-1’ placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol. 2008;160(5):1098–102.

    Article  CAS  Google Scholar 

  • Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatol Treat. 2007;18(5):312–4.

    Article  CAS  Google Scholar 

  • Baskan EB, Yilmaz M, Tunali S, Saricaoglu H. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2009;23(12):1432–4. https://doi.org/10.1111/j.1468-3083.2009.03226.x.

    Article  CAS  PubMed  Google Scholar 

  • Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2006;20(5):548–52. https://doi.org/10.1111/j.1468-3083.2006.01540.x.

    Article  CAS  PubMed  Google Scholar 

  • Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, Barzilai A. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–7.

    CAS  PubMed  Google Scholar 

  • Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041–8. https://doi.org/10.1038/jid.2010.91.

    Article  CAS  PubMed  Google Scholar 

  • Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. 2004;74(4):245–7.

    PubMed  Google Scholar 

  • Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47(3):358–63.

    Article  PubMed  Google Scholar 

  • Calebotta A, Saenz AM, Gonzalez F, Carvalho M, Castillo R. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38(3):217–21.

    Article  CAS  PubMed  Google Scholar 

  • Ch Chaidemenos G, Mourellou O, Koussidou T, Tsatsou F. An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. J Eur Acad Dermatol Venereol. 2007;21(10):1386–91. https://doi.org/10.1111/j.1468-3083.2007.02286.x.

    Article  Google Scholar 

  • Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–8.

    Article  PubMed  Google Scholar 

  • Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285–92. https://doi.org/10.1111/j.1468-3083.2012.04717.x.

    Article  CAS  PubMed  Google Scholar 

  • Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33(11):803–7.

    Article  CAS  PubMed  Google Scholar 

  • Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011a;40(8):616–20.

    Article  CAS  PubMed  Google Scholar 

  • Craythorne EE, Mufti G, duVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011b;65(5):1064–5. https://doi.org/10.1016/j.jaad.2010.06.033.

    Article  PubMed  Google Scholar 

  • Dastgheib L, Sadati MS, Baghernejhad M. Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: a randomized controlled trial. J Dermatolog Treat. 2015;26(1):90–3.

    Article  CAS  PubMed  Google Scholar 

  • Dick SE, Werth VP. Pemphigus: a treatment update. Autoimmunity. 2006;39(7):591–9. https://doi.org/10.1080/08916930600972008.

    Article  CAS  PubMed  Google Scholar 

  • El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55(3):449–59. https://doi.org/10.1016/j.jaad.2006.05.009.

    Article  PubMed  Google Scholar 

  • el-Darouti M, Marzouk S, Abdel Hay R, el-Tawdy A, Fawzy M, Leheta T, et al. The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol. 2009;161(2):313–9.

    Article  CAS  PubMed  Google Scholar 

  • Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7(4):529–41.

    Article  CAS  PubMed  Google Scholar 

  • Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978;114(6):889–94. https://doi.org/10.1001/archderm.1978.01640180023005.

    Article  CAS  PubMed  Google Scholar 

  • Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol. 2002;16(4):353–6.

    Article  CAS  PubMed  Google Scholar 

  • Fiorentino DF, Garcia MS, Rehmus W, Kimball AB. A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol. 2011;147(1):117–8.

    Article  PubMed  Google Scholar 

  • Garcia-Rabasco A, Alsina-Gibert M, Pau-Charles I, Iranzo P. Infliximab therapy failure in two patients with pemphigus vulgaris. J Am Acad Dermatol. 2012;67(5):e196–7.

    Article  PubMed  Google Scholar 

  • Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol. 1996;37(2):93–5.

    Article  CAS  PubMed  Google Scholar 

  • Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47(2–3):247–57.

    Article  CAS  PubMed  Google Scholar 

  • Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008;144(12):1621–4.

    Article  CAS  PubMed  Google Scholar 

  • Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:521–7. https://doi.org/10.2147/ccid.s75908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guillaume J, Roujeau J, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988;124(11):1659–63. https://doi.org/10.1001/archderm.1988.01670110019004.

    Article  CAS  PubMed  Google Scholar 

  • Gürcan HM, Razzaque Ahmed A. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161(4):723–31. https://doi.org/10.1111/j.1365-2133.2009.09246.x.

    Article  CAS  PubMed  Google Scholar 

  • Hall RP 3rd, Fairley J, Woodley D, Werth VP, Hannah D, Streilein RD, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015;172(3):760–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3–6.

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother. 2008;9(9):1519–30.

    Article  CAS  PubMed  Google Scholar 

  • Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699–702.

    Article  CAS  PubMed  Google Scholar 

  • Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 guideline for diagnosis and treatment – guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–14. https://doi.org/10.1111/jdv.12772.

    Article  CAS  PubMed  Google Scholar 

  • Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151(2):200–3. https://doi.org/10.1001/jamadermatol.2014.2421.

    Article  PubMed  Google Scholar 

  • Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855–60.

    Article  CAS  PubMed  Google Scholar 

  • Iraji F, Faghihi G, Siadat AH. The efficacy of acyclovir in treatment of the pemphigus vulgaris. J Res Med Sci. 2013;18(11):976–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005;153(2):448–9.

    Article  CAS  PubMed  Google Scholar 

  • Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol. 2005;141(6):680–2.

    Article  PubMed  Google Scholar 

  • Ljubojevic S, Lipozencic J, Brenner S, Budimcic D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002;16(6):599–603.

    Article  CAS  PubMed  Google Scholar 

  • Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Investig. 2003;111(8):1122–4.

    Article  CAS  PubMed  Google Scholar 

  • Massari P, Duro-Garcia V, Giron F, Hernandez E, Juarez F, Castro C, et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc. 2005;37(2):916–9.

    Article  CAS  PubMed  Google Scholar 

  • Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2–3):119–25.

    Article  CAS  PubMed  Google Scholar 

  • Mentink LF, Mackenzie MW, Toth GG, Laseur M, Lambert FP, Veeger NJ, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial.[Erratum appears in Arch Dermatol. 2006 Aug;142(8):1014 note: dosage error in article text]. Arch Dermatol. 2006;142(5):570–6.

    Article  CAS  PubMed  Google Scholar 

  • Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med. 2000;29(4):145–52.

    Article  CAS  PubMed  Google Scholar 

  • Mignogna MD, Leuci S, Fedele S, Ruoppo E, Adamo D, Russo G, Pagliuca R. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study. Am J Clin Dermatol. 2008;9(5):323–31.

    Article  PubMed  Google Scholar 

  • Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, et al. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2010;162(3):543–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mittmann N, Chan B, Knowles S, Mydlarski PR, Cosentino L, Shear N. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg. 2006;10(5):222–7.

    Article  PubMed  Google Scholar 

  • Momeni AZ, Iraji F, Aminjavaheri M, Emami MR, Momeni A. The use of oral cyclophosphamide with dexamethasone pulse therapy in the treatment of pemphigus vulgaris. J Dermatolog Treat. 2007;18(5):275–8. https://doi.org/10.1080/09546630701449080.

    Article  CAS  PubMed  Google Scholar 

  • Murrell DF. Blistering diseases: clinical features, pathogenesis, treatment. Heidelberg: Springer; 2015.

    Book  Google Scholar 

  • Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol. 2003;49(1):148–50.

    Article  PubMed  Google Scholar 

  • Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol. 1998;134(9):1104–7.

    Article  CAS  PubMed  Google Scholar 

  • Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128(12):1626–30. https://doi.org/10.1001/archderm.1992.04530010064010.

    Article  CAS  PubMed  Google Scholar 

  • Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153(1):222–3.

    Article  CAS  PubMed  Google Scholar 

  • Parmar NV, Kanwar AJ, Minz RW, Parsad D, Vinay K, Tsuruta D, et al. Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study. Indian J Dermatol Venereol Leprol. 2013;79(1):70–6. https://doi.org/10.4103/0378-6323.104672.

    Article  PubMed  Google Scholar 

  • Penneys NS, Eaglstein WH, Frost P. Management of pemphigus with gold compounds: a long-term follow-up report. Arch Dermatol. 1976;112(2):185–7.

    Article  CAS  PubMed  Google Scholar 

  • Poulin Y, Perry HO, Muller SA. Pemphigus vulgaris: results of treatment with gold as a steroid-sparing agent in a series of thirteen patients. J Am Acad Dermatol. 1984;11(5 Pt 1):851–7.

    Article  CAS  PubMed  Google Scholar 

  • Quaresma MV, Bernardes Filho F, Hezel J, Peretti MC, Kac BK, Azulay-Abulafia L. Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent. An Bras Dermatol. 2015;90(3 Suppl 1):51–4. https://doi.org/10.1590/abd1806-4841.20153408.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens a 5-year study. Int J Dermatol. 1990;29(5):363–7. https://doi.org/10.1111/j.1365-4362.1990.tb04765.x.

    Article  CAS  PubMed  Google Scholar 

  • Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–51. https://doi.org/10.1111/bjh.12629.

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112(7):962–70. https://doi.org/10.1001/archderm.1976.01630310024005.

    Article  CAS  PubMed  Google Scholar 

  • Roujeau JC, Andre C, Joneau Fabre M, Lauret P, Flechet ML, Kalis B, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol. 1983;119(3):215–21.

    Article  CAS  PubMed  Google Scholar 

  • Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica. 1984;168(5):219–23.

    Article  CAS  PubMed  Google Scholar 

  • Ryan JG. Pemphigus: a 20-year survey of experience with 70 cases. Arch Dermatol. 1971;104(1):14–20. https://doi.org/10.1001/archderm.1971.04000190016003.

    Article  CAS  PubMed  Google Scholar 

  • Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138(9):1158–62.

    Article  CAS  PubMed  Google Scholar 

  • Sato N, Satake S, Fujiwara H, Ito M, Kameda K, Nagahori E, Igarashi R. Pemphigus vulgaris treated with combined oral cyclosporin and cyclophosphamide. Clin Exp Dermatol. 1998;23(2):92–4. https://doi.org/10.1046/j.1365-2230.1998.00323.x.

    Article  CAS  PubMed  Google Scholar 

  • Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140(1):84–9.

    Article  CAS  PubMed  Google Scholar 

  • Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38(6):659–64. https://doi.org/10.1111/ced.12073.

    Article  CAS  PubMed  Google Scholar 

  • Sondergaard K, Carstens J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus: an update. Ther Apher. 1997;1(2):155–8.

    Article  CAS  PubMed  Google Scholar 

  • Svecova D. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol. 2016;57(2):141–4. https://doi.org/10.1111/ajd.12422.

    Article  PubMed  Google Scholar 

  • Tabrizi MN, Chams-Davatchi C, Esmaeeli N, Noormohammadpoor P, Safar F, Etemadzadeh H, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2007;21(1):79–84.

    Article  CAS  PubMed  Google Scholar 

  • Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  • Tavakolpour S. Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133–42. https://doi.org/10.1016/j.intimp.2017.10.027.

    Article  CAS  PubMed  Google Scholar 

  • Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–21. https://doi.org/10.1111/bjd.12474.

    Article  CAS  PubMed  Google Scholar 

  • Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132(12):1435–9. https://doi.org/10.1001/archderm.1996.03890360021005.

    Article  CAS  PubMed  Google Scholar 

  • Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, Jacobus D. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  • Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–24. https://doi.org/10.1007/s00403-013-1409-7.

    Article  CAS  PubMed  Google Scholar 

  • Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of New South Wales, Sydney, NSW, Australia

    Esther Q. Wang

  2. Department of Dermatology at St George Hospital, University of New South Wales, Kogarah, Sydney, NSW, Australia

    Dedee F. Murrell

Authors
  1. Esther Q. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dedee F. Murrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dedee F. Murrell .

Editor information

Editors and Affiliations

  1. Dept Dermatology, 110 Surge Bldg, UCSF School of Medicine Dept Dermatology, 110 Surge Bldg, San Francisco, CA, USA

    Howard Maibach

  2. Department of Dermatology, University of California, San Francisco Department of Dermatology, San Francisco, CA, USA

    Nily Osman

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Wang, E.Q., Murrell, D.F. (2019). Pemphigus Vulgaris: An Evidence-Based Treatment Update. In: Maibach, H., Osman, N. (eds) Cutaneous Biometrics. Springer, Cham. https://doi.org/10.1007/978-3-319-56591-0_15-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56591-0_15-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56591-0

  • Online ISBN: 978-3-319-56591-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation